REGN4336 / Regeneron - LARVOL DELTA

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - P1/2 | N=265 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Castration-Resistant Prostate Cancer • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • PD-L1

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - P1/2 | N=265 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals

New P1/2 trial • Castration-Resistant Prostate Cancer • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • PD-L1

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer (clinicaltrials.gov) - P1/2 | N=228 | Recruiting | Sponsor: Regeneron Pharmaceuticals | N=370 ➔ 228 | Trial completion date: Jan 2027 ➔ Mar 2030 | Trial primary completion date: Jan 2027 ➔ Mar 2030

Enrollment change • Trial completion date • Trial primary completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (ASCO-GU 2025) - P1/2 | "Module 1 began with REGN4336 administered SC; in addition, Modules 1–3 may evaluate REGN4336 administered IV (+ sarilumab [anti–IL-6] for CRS prophylaxis) to compare tolerability, PK, and immunogenicity across routes. This is the first study to evaluate combined ×CD3 + ×CD28 bsAb in mCRPC. As of Sept 12, 2024, 35 pts have been enrolled, including 4 in Module 3."

Clinical • Combination therapy • IO biomarker • Metastases • P1/2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer (clinicaltrials.gov) - P1/2 | N=370 | Recruiting | Sponsor: Regeneron Pharmaceuticals | N=199 ➔ 370 | Trial completion date: Aug 2026 ➔ Jan 2027 | Trial primary completion date: Aug 2026 ➔ Jan 2027

Combination therapy • Enrollment change • Metastases • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer. (ASCO-GU 2023) - P1/2, P3 | "This study is currently open to enrollment. Clinical trial information: NCT03088540."

Clinical • Combination therapy • Metastases • P1/2 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer. (ASCO 2022) - P1/2, P3 | "At selected sites, PSMA positron emission tomography/computed tomography scans will be performed at predefined timepoints on study. This study is currently open to enrollment."

Clinical • Combination therapy • P1/2 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor